Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

DOI Full Paper Access

246

Citations

34

References

2017

Year

Michel Bazinet, Victor Pântea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Jeffrey H. Albrecht, Peter Schmid, Frédéric Le Gal, Emmanuel Gordien, Adalbert Krawczyk,

The Lancet. Gastroenterology & hepatology

Abstract

Replicor.

References

	Year	Citations

Page 1